esas for the management of lower-risk mds
Published 2 years ago • 44 plays • Length 2:37Download video MP4
Download video MP3
Similar videos
-
1:48
the impact of esas in lower-risk mds
-
11:53
the optimal treatment of lower risk mds
-
1:20
the current standard of care for patients with lower-risk mds
-
0:56
the promise of luspatercept for the treatment of lower-risk mds
-
11:33
treatment algorithm for low-risk mds
-
49:25
myelodysplastic syndrome (mds) and anemia
-
7:54
patient/caregiver stories - living with mds
-
55:30
mds treatment - side effect management & ask a hematologist
-
1:14
real-world treatment patterns of patients with low-risk mds reinitiating esas
-
1:59
the role of inflammatory signaling pathways in lower-risk mds
-
1:02
emerging treatment options for lower- and higher-risk mds and ongoing trials
-
0:52
the need to incorporate disease-modifying drugs in lower-risk mds
-
2:04
the role of esas agents in low-risk mds
-
25:10
management of lower-risk mds without del5q and refractory to esas
-
1:34
perspectives on the management of low and high-risk mds
-
2:25
approaching esa failure in patients with lower-risk mds
-
3:38
a new set of treatment options for low-risk mds
-
1:50
considerations for risk-adapted therapy in lower-risk mds
-
1:16
state of the art: mds
-
1:57
safety and efficacy of sx-682 in hma failure mds
-
4:32
recent advances in the treatment of lr-mds: commands and imerge trial data
-
2:04
state-of-the-art treatment for hr-mds